Ionis Pharmaceuticals' stock fell over 25% after its Q3 earnings report, despite beating revenue and EPS expectations and reaffirming 2026 guidance. The sharp decline was driven by a more than 50% cut in 2026 sales guidance for its drug Tryngolza, due to slower uptake and strong competition. Major setbacks including partner trial failures and a disappointing product launch have raised doubts about Ionis' growth prospects. The analyst downgraded the stock to Hold, citing ongoing losses and uncertain revenue despite some pipeline progress.
As of Nov 10, 2026 05:21 WIB, Ionis Pharmaceuticals (IONS) trades at USD 31.00 on Pluang, down 21.36% in one day. Despite the sharp drop, Pluang order activity shows 100% buy interest, indicating some investors are still accumulating the stock. The market cap stands at $6.55 billion, reflecting significant investor attention despite recent setbacks.
Ionis Pharmaceuticals lowered its full-year 2026 sales guidance for its drug TRYNGOLZA from $100-$110 million to about $50 million, citing slower-than-expected market adoption. The drug had generated $32 million in sales in the first half of 2026 but...
Ionis Pharmaceuticals cut its 2026 sales forecast for TRYNGOLZA from $100-110 million to about $50 million due to a slower-than-expected commercial launch. This significant downgrade raised concerns about whether the company had previously disclosed ...
Ionis Pharmaceuticals sharply reduced its revenue guidance for one of its main drugs due to weak sales, causing its stock to fall significantly in premarket trading. This revenue cut overshadows the company's otherwise solid earnings report. The lowe...
